Please assess the completion status of the following clinical trial:

Trial Title: A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil® in Patients With Psoriasis Vulgaris

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed and dated informed consent has been obtained~* Subjects with a diagnosis of psoriasis vulgaris with preferably three lesions (plaques) located on arms, legs and/or trunk or at least two lesions (plaques) located on arms, legs and/or trunk. For subjects with three lesions, each lesion must have a size suitable to accommodate 2 test sites (test site area 5 cm2, distance between two test sites at least 2 cm). For subjects with two lesions, one lesion must have a size suitable to accommodate 4 test sites, and the other lesion must accommodate 2 test sites.~* Age 18 years or above~* Outpatients~* Female subjects must be of either~  * non-childbearing potential, i.e. post-menopausal or have a confirmed clinical history of sterility (e.g. the subject is without a uterus or has tubal ligation) or,~ * child-bearing potential provided there is a confirmed negative pregnancy test prior to trial treatment to rule out pregnancy.~Exclusion Criteria:~* Female subjects who are breast feeding~* Systemic treatment with biological therapies, whether marketed or not, with a possible effect on psoriasis vulgaris within the following time periods prior to randomisation:~  * Etanercept - within 4 weeks prior to randomisation and during the trial~ * Adalimumab, infliximab - within 8 weeks prior to randomisation and during the trial~ * Ustekinumab - within 16 weeks prior to randomisation and during the trial~ * Other products - within 4 weeks/5 half-lives prior to randomisation and during the trial (whichever is longer)~* Systemic treatment with all other therapies than biologicals, with a potential effect on psoriasis vulgaris (e.g., corticosteroids, retinoids, immunosuppressants) within the 4-week period prior to randomisation and during the trial~* Subjects using phototherapy within the following time periods prior to randomisation and during the trial:~  * PUVA: 4 weeks~ * UVB: 2 weeks~* Subjects using one of the following topical drugs for the treatment of psoriasis within the 4 week period prior to randomisation and during the trial:~  * Potent or very potent (WHO group III-IV) corticosteroids~* Subjects using one of the following topical drugs for the treatment of psoriasis within 2 weeks prior to randomisation and during the trial:~  * WHO group I-II corticosteroids (except if used for treatment of scalp and/or facial psoriasis)~ * Topical retinoids, Vitamin D analogues, Topical immunomodulators (e.g. calcineurin inhibitors), Tar products, Salicylic acid~* Subjects using emollients on the selected plaques within 1 week before randomisation and during the trial~* Initiation of, or expected changes to concomitant medication that may affect psoriasis vulgaris (e.g., beta blockers, antimalarial drugs, lithium and ACE inhibitors) within 2 weeks prior to the randomisation and during the trial~* Subjects with current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LEO 90100 Aerosol foam (Type: ACTIVE_COMPARATOR): Calcipotriol (as monohydrate) 50 mcg/g and betamethasone (as dipropionate) 0.5 mg/g (LEO 90100 Aerosol foam)
- Betesil® 2.25 mg (Type: ACTIVE_COMPARATOR): Betamethasone (as valerate). Each 7.5 cm x 10 cm medicated plaster contains: 2.250 mg of betamethasone valerate (corresponding to 1.845 mg of betamethasone).(Betesil® )

Based on this trial design, predict the completion outcome and termination type (if applicable).